Suven secures product patents in Israel, Mexico

Suven Life Sciences announced that they have been granted product patent for one product from Israel and for another from Mexico.

The grant was corresponding to the new chemical entities which are used for the treatment of disorders related to Neurodegenerative diseases. These patents are valid through 2032. These granted patent claims include the class of selective 5-HT4 compounds.

The product is being developed as a therapeutic agent and is used in the treatment of cognitive impairment related to neurodegenerative impairment like Attention deficient hyperactivity disorder (ADHD), Alzheimer’s disease, Schizophrenia, Parkinson’s and Huntington’s disease.

With these new grants, Suven has a total of ten granted patents from Israel and 21 granted patent products from Mexico.

All these patents are exclusive property of Suven which was achieved by internal discovery research efforts. However, the products out of these inventions can easily be out-licensed in various phases of clinical development.